Literature DB >> 20170730

The role of REST in transcriptional and epigenetic dysregulation in Huntington's disease.

Noel J Buckley1, Rory Johnson, Chiara Zuccato, Angela Bithell, Elena Cattaneo.   

Abstract

Huntington's disease (HD) is a devastating disorder that affects approximately 1 in 10,000 people and is accompanied by neuronal dysfunction and neurodegeneration. HD manifests as a progressive chorea, a decline in mental abilities accompanied by behavioural, emotional and psychiatric problems followed by, dementia, and ultimately, death. The molecular pathology of HD is complex but includes widespread transcriptional dysregulation. Although many transcriptional regulatory molecules have been implicated in the pathogenesis of HD, a growing body of evidence points to the pivotal role of RE1 Silencing Transcription Factor (REST). In HD, REST, translocates from the cytoplasm to the nucleus in neurons resulting in repression of key target genes such as BDNF. Since these original observations, several thousand direct target genes of REST have been identified, including numerous non-coding RNAs including both microRNAs and long non-coding RNAs, several of which are dysregulated in HD. More recently, evidence is emerging that hints at epigenetic abnormalities in HD brain. This in turn, promotes the notion that targeting the epigenetic machinery may be a useful strategy for treatment of some aspects of HD. REST also recruits a host of histone and chromatin modifying activities that can regulate the local epigenetic signature at REST target genes. Collectively, these observations present REST as a hub that coordinates transcriptional, posttranscriptional and epigenetic programmes, many of which are disrupted in HD. We identify several spokes emanating from this REST hub that may represent useful sites to redress REST dysfunction in HD. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20170730     DOI: 10.1016/j.nbd.2010.02.003

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  66 in total

Review 1.  Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB.

Authors:  Tz-Chuen Ju; Yow-Sien Lin; Yijuang Chern
Journal:  Cell Mol Life Sci       Date:  2012-05-25       Impact factor: 9.261

Review 2.  REST and CoREST are transcriptional and epigenetic regulators of seminal neural fate decisions.

Authors:  Irfan A Qureshi; Solen Gokhan; Mark F Mehler
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

3.  In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.

Authors:  Elizabeth A Thomas; Giovanni Coppola; Bin Tang; Alexandre Kuhn; SoongHo Kim; Daniel H Geschwind; Timothy B Brown; Ruth Luthi-Carter; Michelle E Ehrlich
Journal:  Hum Mol Genet       Date:  2010-12-20       Impact factor: 6.150

Review 4.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

5.  Phosphatase activity of small C-terminal domain phosphatase 1 (SCP1) controls the stability of the key neuronal regulator RE1-silencing transcription factor (REST).

Authors:  Nathaniel Tate Burkholder; Joshua E Mayfield; Xiaohua Yu; Seema Irani; Daniel K Arce; Faqin Jiang; Wendy L Matthews; Yuanchao Xue; Yan Jessie Zhang
Journal:  J Biol Chem       Date:  2018-09-14       Impact factor: 5.157

Review 6.  Advances in epigenetics and epigenomics for neurodegenerative diseases.

Authors:  Irfan A Qureshi; Mark F Mehler
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

7.  Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice.

Authors: 
Journal:  Nat Neurosci       Date:  2017-03-20       Impact factor: 24.884

Review 8.  The emerging field of epigenetics in neurodegeneration and neuroprotection.

Authors:  Jee-Yeon Hwang; Kelly A Aromolaran; R Suzanne Zukin
Journal:  Nat Rev Neurosci       Date:  2017-05-18       Impact factor: 34.870

9.  Diagnosing and Treating Nervous System Disorders by Targeting Novel Classes of Non-coding RNAs.

Authors:  Irfan A Qureshi; Mark F Mehler
Journal:  Int Drug Discov       Date:  2011 Jun-Jul

10.  Dysregulated A to I RNA editing and non-coding RNAs in neurodegeneration.

Authors:  Minati Singh
Journal:  Front Genet       Date:  2013-01-22       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.